Endometrial cancer is the most common gynecologic malignancy. PTEN is a negative regulator of PI3K signaling and is deficient in > 50% of primary human endometrial cancer. Amplification of ERBB2 promotes tumorigenesis and pathogenesis of several human cancers. However, the effect of ERBB2 targeting has not been studied in endometrial cancer with PTEN mutations. The murine model PgrErbb2Pten (Erbb2 Pten) was developed to evaluate the effect of ERBB2 targeted therapy in endometrial cancer with PTEN deficiency. Histopathological and molecular analysis was performed for Pten and Erbb2Pten mice. Histopathological analysis revealed that Erbb2Pten mice significantly reduced development and progression of endometrial cancer compared to Pten mice. Furthermore, percentage of proliferative cells in Erbb2Pten mice revealed anti-tumorigenic effect of Erbb2 ablation compared to Pten mice. Our results demonstrate that Erbb2 ablation reveals a significant suppression of tumorigenesis on endometrial cancer of Pten mice. Our results suggest that Erbb2 functions as an oncogene in endometrial cancer of Pten mice implying that Erbb2 targeting can be used as an effective therapeutic approach for treatment of endometrial cancer with PTEN deficiency to hinder cancer development.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s43032-024-01546-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Transforming the care of people with Lynch syndrome: a system-wide approach.
BMJ Oncol
October 2023
Translational and Clinical Research, Newcastle University Faculty of Medical Sciences, Newcastle upon Tyne, UK.
The English National Lynch Syndrome transformation project: an NHS Genomic Medicine Service Alliance (GMSA) programme.
BMJ Oncol
October 2023
Clinical Genetics, Guy's and St Thomas' NHS Foundation Trust, London, UK.
Objective: In England, through the Genomic Medicine Service Alliances (GMSAs), a national transformation project aims to embed robust pathways to deliver universal Lynch syndrome (LS) testing for patients with colorectal and endometrial cancers. Prior to commencement of the project, there was evidence of variation and low testing levels in eligible patients which is consistent with other health systems; however, we believe this is amenable to systematic improvement with responsibility for testing delivery by local cancer teams supported by regional infrastructure.
Methods And Analysis: A project team and national oversight group was formed in May 2021 with membership including 21×cancer alliances, 7×GMSAs, charities and other stakeholders who agreed key performance indicators.
Objective: To explore the impact of molecular subtype in endometrial cancer (EC) on CD8+T cell densities. Furthermore, this work will test the assumption that all mismatch repair deficient (MMRd) tumours are immunologically similar which would enable current trial data to be generalised to all MMRd ECs.
Methods And Analysis: All tumours were characterised into the four clinical molecular subtypes.
Implications of hormonal carcinogenesis for transgender and gender-diverse people undergoing gender-affirming hormone therapy: an up-to-date review.
BMJ Oncol
May 2024
Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Transgender and gender-diverse (TGD) individuals face an elevated risk of cancer in comparison with the general population. This increased risk is primarily attributed to an imbalanced exposure to modifiable risk factors and a limited adherence to cancer screening programmes, stemming from historical social and economic marginalisation. Consequently, these factors contribute to poorer clinical outcomes in terms of cancer diagnosis and mortality.
View Article and Find Full Text PDFUterine organoids reveal insights into epithelial specification and plasticity in development and disease.
Proc Natl Acad Sci U S A
February 2025
Department of Obstetrics, Gynecology, and Women's Health, University of Missouri, Columbia, MO 65211.
Understanding how epithelial cells in the female reproductive tract (FRT) differentiate is crucial for reproductive health, yet the underlying mechanisms remain poorly defined. At birth, FRT epithelium is highly malleable, allowing differentiation into various epithelial types, but the regulatory pathways guiding these early cell fate decisions are unclear. Here, we use neonatal mouse endometrial organoids and assembloid coculture models to investigate how innate cellular plasticity and external mesenchymal signals influence epithelial differentiation.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!